The efficacy of neratinib combined with paclitaxel was compared with tratuzumab plus paclitaxel in naïve patients with HER2-positive ABC in the NEfERT-T randomized phase III trial (NCT00915018) [47]. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.